Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics develops investigational therapies for liver and viral diseases as a clinical-stage biotechnology company. Its news centers on programs for chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, obesity, and coronavirus infections, including pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675.
Recurring updates cover clinical and nonclinical data, regulatory designations, scientific-conference presentations, quarterly financial results, research and development spending, licensing agreements, and equity compensation actions. Company releases also describe the Phase 2 B-SUPREME study of pevifoscorvir sodium, FDA Fast Track Designation for chronic HBV infection, and the exclusive license agreement for Greater China with Xiamen Amoytop Biotech.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) has announced a public offering of 4,000,000 shares of common stock, with an additional 600,000 shares available for underwriters. The offering is contingent upon market conditions and is managed by J.P. Morgan, Jefferies, and Piper Sandler. A registration statement has been filed with the SEC, but remains unapproved. Aligos aims to lead in treatments for viral infections and liver diseases, focusing on chronic hepatitis B and nonalcoholic steatohepatitis. The company emphasizes potential risks related to market conditions and drug development uncertainties.
Aligos Therapeutics (ALGS) presented preliminary data for its S-antigen Transport-inhibiting Oligonucleotide Polymer, ALG-010133, at the EASL Digital International Liver Congress 2021. The Phase 1a/b trial showed that ALG-010133 was safe and well-tolerated in healthy volunteers, with no serious adverse events. Aligos also showcased additional CHB programs, indicating strong progress in chronic hepatitis B treatment development. The company plans to advance clinical trials for its candidates and expects to share further antiviral data in the second half of 2021.
Aligos Therapeutics (Nasdaq: ALGS) is set to present five scientific abstracts at the EASL Digital International Liver Congress™ 2021 from June 23-26, 2021. The presentations will showcase their progress on chronic hepatitis B (CHB) treatments, including two candidates in Phase 1b studies. Both the STOPS™ molecule and CAPSID Assembly Modulator (CAM) are being evaluated in CHB patients, with preliminary data expected by H2 2021. Additionally, ASO and siRNA candidates are on track for clinical development in H2 2021 and H1 2022, respectively.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced promising results from its study on ALG-000184, presented at the HBV-TAG 2021 Conference. Subjects receiving 100 mg of ALG-000184 for 14 days showed a mean reduction of 2.9 log10 IU/mL in HBV DNA levels. Notably, 50% of subjects had HBV DNA below the lower limit of quantitation. The drug was well tolerated and demonstrated significant antiviral activity. Aligos plans to share more data later this year and continue developing its CHB programs.
Aligos Therapeutics, a clinical stage biopharmaceutical company, announced that its CEO, Lawrence Blatt, will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, from 2:00 to 2:25 PM ET. The presentation will include a virtual Q&A session. Interested parties can access the event via a webcast. The conference will feature over 400 companies and 3,000 investors discussing healthcare trends and investment opportunities.
Aligos Therapeutics reported its Q1 2021 financial results, revealing a net loss of $27.7 million or $0.74 per share, up from a loss of $20.0 million or $7.56 per share in Q1 2020. R&D expenses increased to $22.9 million, driven by clinical trials for drug candidates ALG-010133 and ALG-000184. General and administrative expenses rose to $5.8 million. Cash reserves decreased from $243.5 million at the end of 2020 to $213.4 million. Despite pandemic challenges, Aligos remains on track with its clinical programs, aiming to commence trials for several candidates in the coming months.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced it will release its first quarter 2021 financial results on May 10, 2021, after market close. The company focuses on developing novel therapeutics for viral and liver diseases, particularly chronic hepatitis B and nonalcoholic steatohepatitis. Founded in 2018, Aligos aims to leverage its team's extensive drug development experience to advance its pipeline of targeted antiviral therapies.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the appointment of James Scopa, J.D., MBA, to its board of directors on April 27, 2021. CEO Lawrence Blatt stated this addition supports Aligos' growth as it transitions towards mid-stage clinical trials for chronic hepatitis B. Scopa brings over 30 years of life sciences experience as an investor and advisor, positioning him to provide strategic guidance. He has previously held significant roles at MPM Capital and Deutsche Banc Alex. Brown, enhancing Aligos' leadership as it expands in viral and liver disease therapies.
Aligos Therapeutics has commenced patient dosing in its ongoing study of ALG-000184, a drug candidate targeting chronic hepatitis B (CHB). This study evaluates ALG-000184's ability to inhibit viral replication by measuring HBV DNA and RNA levels. The company aims to combine ALG-000184 with other therapies to achieve better treatment outcomes. Preliminary data from previous trials indicate a favorable safety profile. Initial data on safety and antiviral activity are expected in the second half of 2021, contributing to Aligos' goal of improving CHB treatment regimens.
Aligos Therapeutics (NASDAQ: ALGS) reported strong financial results for Q4 and the full year 2020, with cash reserves of $243.5 million following a successful IPO raising $167.2 million. The company advanced two drug candidates, ALG-010133 and ALG-000184, into clinical trials for Chronic Hepatitis B (CHB) and expects to generate safety and antiviral activity data in 2021. However, net losses reached $108.5 million for the year, up from $52.3 million in 2019, reflecting increased R&D expenses of $79.9 million.